A group in the U.K. has published a consensus statement on the use of the atypical antipsychotic aripiprazole for acute mania (Aitchison et al. J Psychopharmacol 2009; 23: 231-240).  Unlike other atypical antipsychotic agents (clozapine, risperidone, olanzapine, quetiapine, ziprasidone), aripiprazole acts as a partial agonist at the dopamine D2 and serotonin 5HT-1A and 5HT-2C receptors, and as a 5HT-2A antagonist (for a recent review see Pae CU. Expert Opin Drug Saf 2009; 8: 373-386).